Regulatory News
Wednesday, January 11, 2017
BRIEF-Sangamo Therapeutics receives orphan drug designation from the FDA for SB-318 genome editing treatment for MPS I
* Sangamo Therapeutics receives orphan drug designation from
the FDA for SB-318 genome editing treatment for MPS I
Read more
No comments:
Post a Comment
‹
›
Home
View web version
No comments:
Post a Comment